Purchase this article with an account.
N. G. Anderson, B. Panasuk; Endophthalmitis Rate Following Intravitreal Injection Using Topical 2% Viscous Lidocaine Anesthesia. Invest. Ophthalmol. Vis. Sci. 2007;48(13):678.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the endophthalmitis rate following intravitreal injection using topical 2% viscous lidocaine anesthesia.
Retrospective chart review. The charts of all patients undergoing intravitreal injection between August 15, 2005 and October 15, 2006 were reviewed.
A total of 379 consecutive injections were performed on 188 patients during the study period. All patients underwent topical anesthesia with 2% viscous lidocaine (Roxane Laboratories, Columbus, Ohio). One-hundred twenty ranibizumab injections were performed. One-hundred nineteen pegaptanib injections were performed. Ninety-one triamcinolone acetodine injections were performed. Forty-nine bevacizumab injections were performed. No cases of endophthalmitis occurred during the study period.
No cases of endopthalmitis occurred following intravitreal injection using topical 2% viscous lidocaine anesthesia. The endophthalmitis rate using topical viscous lidocaine anesthesia for intravitreal injection does not appear to be higher than rates reported using previously published anesthesia techniques.
This PDF is available to Subscribers Only